Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Short Interest Up 116.5% in January

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 130,715 shares, an increase of 116.5% from the December 31st total of 60,376 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average trading volume of 149,034 shares, the short-interest ratio is presently 0.9 days. Based on an average trading volume of 149,034 shares, the short-interest ratio is presently 0.9 days. Approximately 0.8% of the shares of the stock are sold short.

Institutional Trading of Brainsway

A number of large investors have recently modified their holdings of the company. ARK Investment Management LLC raised its holdings in Brainsway by 6.1% in the second quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock worth $2,628,000 after purchasing an additional 11,498 shares in the last quarter. Huntleigh Advisors Inc. grew its position in shares of Brainsway by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after buying an additional 4,143 shares during the last quarter. Eagle Global Advisors LLC raised its stake in shares of Brainsway by 9.4% during the 4th quarter. Eagle Global Advisors LLC now owns 81,303 shares of the company’s stock worth $1,546,000 after acquiring an additional 6,977 shares in the last quarter. Palumbo Wealth Management LLC lifted its position in Brainsway by 37.9% during the fourth quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock valued at $310,000 after acquiring an additional 4,483 shares during the last quarter. Finally, Y.D. More Investments Ltd lifted its position in Brainsway by 559.8% during the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock valued at $2,187,000 after acquiring an additional 97,537 shares during the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on BWAY shares. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. HC Wainwright upped their price target on shares of Brainsway from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Northland Securities set a $30.00 price objective on shares of Brainsway in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $30.00.

Brainsway Price Performance

Shares of NASDAQ BWAY opened at $23.38 on Friday. Brainsway has a 1 year low of $7.84 and a 1 year high of $25.65. The company has a market cap of $457.78 million, a P/E ratio of 77.93 and a beta of 1.19. The firm has a 50-day simple moving average of $19.84 and a two-hundred day simple moving average of $16.53.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.03). The business had revenue of $13.51 million during the quarter, compared to the consensus estimate of $13.04 million. Brainsway had a net margin of 12.73% and a return on equity of 9.46%. As a group, equities research analysts expect that Brainsway will post 0.08 EPS for the current year.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.